Technology · Overview
one ambition
S2Medical’s technology rests on two pillars: a platform of own developed antimicrobial peptides, and a minimally invasive skin grafting technology. Together they follow the wound from infection control to closure. This page is the overview; each platform has its own page with the full detail.
Technologies
- Platform 01
- ADMERCIN™ · PEPTIDES · PRECLINICAL
- Platform 02
- INSTAGRAFT® · GRAFTING · IN DEVELOPMENT
- Mechanism
- PHYSICAL, NOT PHARMACOLOGICAL
- Patents
- 18 EU COUNTRIES · TO 2039
The platforms
peptides and grafting
Platform 01 · Antimicrobial peptides
admercin™
Our own developed antimicrobial peptides act purely physically on the bacterial membrane rather than through a metabolic pathway [2]. In preclinical and in vitro studies they have shown strong antibacterial effects, and the platform is patented in 18 European countries [7].
Platform 02 · Skin grafting
instagraft®
Our own skin grafting technology, developed in the subsidiary Instagraft AB. A minimally invasive route to re-epithelialisation, built to close the wound without creating a second wound at a donor site, on the heritage of our biosynthetic cellulose dressing.
How they fit together
every step to healing
The platforms are not isolated projects. Together with our products they follow the wound along a single pathway: prepare, fight infection, close.
01
Prepare
Debridement instruments cleanse the wound and remove devitalized tissue.
02
Fight infection
The peptide platform targets multi-resistant bacteria with a purely physical mechanism.
03
Close
Minimally invasive grafting supports re-epithelialisation of the wound.